ERBB2 and breast carcinoma: Oncotype DX (Genomic Health, Redwood, CA, USA), a gene expression profile consisting of 16 cancer-related genes (AURKA, BAG1, BCL2, BIRC5, CCNB1, CD68, CTSL2, ERBB2, ESR1, GRB7, GSTM1, MKI67, MMP11, MYBL2, PGR, SCUBE2), has been officially recommended by the National Comprehensive Cancer Network (NCCN), and widely used to calculate the recurrence score (RS) for ER+ breast cancer patients on a scale of 0–100, with ratings of low (0–10), intermediate (11–25), and high risk (>26) [14].